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Oropharyngeal cancerAbstract Purpose: Several hypotheses have been proposed to explain the relatively good
prognosis of patients with a human papillomavirus (HPV)-positive oropharyngeal squamous
cell carcinoma (OPSCC) and one of these is a higher sensitivity to (chemo)radiation. Previous
studies have suggested that treatment failure in OPSCC patients is caused by resistance of can-
cer stem cells (CSCs). The purpose of this study was to evaluate the association between the
number of CSCs and prognosis in HPV-positive OPSCC patients.
Experimental design: All OPSCC patients (n = 711) treated between 2000 and 2006 in two
Dutch university hospitals were included. Presence of HPV in a tumour tissue specimen
was tested by p16-immunostaining followed by HPV DNA GP5+/6+polymerase chain reac-
tion (PCR). The presence and intensity of tumour CSC markers CD44 and CD98 were deter-
mined by immunohistochemistry and semiquantitative scoring was performed. Overall
survival (OS) and progression-free survival (PFS) rates were compared between patients with
low and high CD44/CD98 expression in relation to HPV status.
Results: HPV-positive tumours showed a lower percentage of cells with CD44 and CD98
expression than HPV-negative tumours (p < 0.001, v2-test). Within the group of patients withCenter,
766 M.M. Rietbergen et al. / European Journal of Cancer 50 (2014) 765–773HPV-positive OPSCC, a high percentage of CD98-positive tumour cells was associated with a
significantly worse 5-year OS and PFS (OS: 36.4% and PFS: 27.3%) compared to patients with
a low percentage of CD98-positive cells (OS: 71.9% and PFS: 70.5%, respectively) (p < 0.001).
Conclusions: HPV-positive OPSCCs harbour fewer cells expressing the CSC enrichment
markers CD44 and CD98. Furthermore, OS and PFS were significantly worse for patients
with HPV-positive OPSCC with a high percentage of CD98-positive cells.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Infection with high-risk human papillomavirus
(HPV) is aetiologically linked to the development of
head and neck squamous cell carcinomas (HNSCCs),
particularly those carcinomas that arise in the oropha-
ryngeal region. HPV-positive oropharyngeal squamous
cell carcinomas (OPSCCs) are characterised by an epide-
miologic, demographical and clinical profile that devi-
ates from that of HPV-negative OPSCCs [1,2]. The
most important difference is related to prognosis, which
is markedly better for patients with an HPV-positive
tumour compared to those with an HPV-negative
tumour. Several hypotheses have been proposed to
explain the improved outcome for patients with HPV-
positive OPSCC, including an increased sensitivity to
radiation and chemotherapy, differences in the role of
the host immune system and the absence of field canceri-
sation [3–6]. In this study, we further evaluated the role
of cancer stem cells (CSCs) in HPV-positive OPSCCs.
Previous studies suggest that treatment failure in
HNSCC patients might be the consequence of therapy
resistance of cancer stem cells (CSCs) [7]. CSCs represent
a small subpopulation of tumour cells that maintain
tumour growth by fuelling the expansion of the malig-
nant cell population infinitely [8]. CSCs can be distin-
guished from the bulk of the tumour based on
differential expression of protein markers on the cell
membrane. A large body of evidence indicates that
HNSCC cells expressing high levels of the CD44 antigen
possess CSC properties. CD44high HNSCC cells have
been shown to initiate tumour growth in mice muchmore
efficiently than CD44low cells, indicating that CSCs are
enriched in the CD44high subpopulation of HNSCC [9].
Moreover, a high expression of CD44 seems associated
with a poor prognosis in patients with HNSCC [10].
Recently, we examined CD98 as a novel, putative
CSC enrichment marker in HNSCC and showed that
CD98high cells, in contrast to CD98low cells, are able to
generate tumours in immune-deficient mice [11]. Studies
in a multitude of cancer types showed a higher CD98
expression in progressive and metastatic tumours, which
relates to a poor prognosis [12–17].
Recently, it was shown that a small subpopulation of
cells with CSC properties could also be isolated from an
HPV-positive head and neck cancer cell line [18]. As
patients with an HPV-positive OPSCC respond better
to treatment and have a more favourable prognosiscompared to patients with an HPV-negative OPSCC,
we hypothesised that HPV-positive OPSCCs, might
have relatively low levels of CSCs. To test this hypothe-
sis, we performed CD44 and CD98 immunostaining on
a cohort of OPSCC patients with known HPV status
[19]. Furthermore, we evaluated whether CD44 and
CD98 expression could be of potential relevance for pre-
dicting treatment outcome in patients with HPV-posi-
tive OPSCC.2. Materials and methods
2.1. Patients and tumour samples
To evaluate CD44/CD98 immunostaining and the
relation to HPV, a test cohort was composed, which
included 88 fresh-frozen, pre-treatment OPSCC samples
of patients treated in the period 2008–2011. Eligible
samples included histopathologically confirmed invasive
squamous cell carcinoma of the oropharynx (Interna-
tional classification of diseases for Oncology, [ICD-10]
codes C019, C051, C052, C090–C099 and C100–C109).
These OPSCCs were previously tested for HPV using
an HPV E6 mRNA reverse-transcriptase polymerase
chain reaction (RT-PCR) [19].
To further study the association between survival and
CD44/CD98 expression, all patients (n = 711) treated
between 2000 and 2006 at two Dutch university hospi-
tals were included. Patients were identified through the
Dutch Cancer Registries. Patient characteristics and
clinical outcome were obtained from the patient files.
HPV detection was performed using pre-treatment for-
malin-fixed, paraffin-embedded (FFPE) biopsies [20].
A sample was scored HPV-positive based on a positive
p16INK4A-immunohistochemistry (p16-IHC) and a sub-
sequent positive GP5+/6+ HPV DNA PCR, according
to a previously validated algorithm [19]. Approval for
this retrospective study was obtained from the Institu-
tional Review Board and the study adheres to the guide-
lines for proper secondary use of human tissue specimen
(www.federa.org).2.2. Immunohistochemical staining of CD44 and CD98
Formalin-fixed paraffin-embedded sections of
HNSCC tumour biopsies were deparaffinised and sub-
jected to Tris/EDTA (10 mM/1 mM, pH 9.0) antigen
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oped at our laboratory [21]) and anti-CD98 (clone H-
300, Santa Cruz Biotechnology), were diluted in PBS
containing 2% goat serum and incubated overnight at
4 C. Afterwards, the BrightVision +Poly-HRP-Anti
Ms/Rb/Rt IgG kit (Immunologic BV, Duiven, The
Netherlands) was employed according to the description
of the manufacturer. The staining was developed with
diaminobenzidine and H2O2 as chromogen. Sections
were counterstained with haematoxylin and cover
slipped with Kaiser’s glycerine. To correct for the differ-
ences in dimensions of the biopsies, decisions on CD44
and CD98 scores were based on a single area that con-
tained viable tissue with over 70% HNSCC cells.2.3. Evaluation of immunohistochemical staining
CD44 and CD98 expression were evaluated by stain-
ing intensity and by percentage of positive cells. Percent-
age of CD44-positive cells was evaluated semi-
quantitatively, and classified according to the percentage
of malignant cells: 1 (610% of tumour cells stained), 2
(11–50% stained), 3 (51–75% stained) or 4 (>75%
stained) [10]. Percentage of CD98-positive cells was clas-
sified differently, in accordance to previous reports, as
overall staining was lower: 1 (610% of tumour cells
stained), 2 (11-25% stained), 3 (26–50% stained) and 4
(>50% stained) [15,16]. The intensity of CD44 and
CD98 staining was scored separately and evaluated as
absent (0), weak (1), moderate (2) or strong (3) [10].
Three investigators independently classified the per-
centage of positive cells and staining intensity in all
cases, without prior knowledge of the clinical data.
The data are presented as the mean of the three
observations.2.4. Statistical analyses
Probability values of <0.05 indicated a statistically
significant difference. A Mann-Whitney U Test was per-
formed to compute the CD44/CD98 expression differ-
ences between HPV-positive and HPV-negative
OPSCCs. Differences in patient characteristics between
HPV-positive and HPV-negative cases were assessed
using the Pearson v2-test or Student’s t-test. Bonferroni
correction was used to compare subgroups for specific
variables. The end-points were overall survival (OS)
and progression-free survival (PFS). OS was defined as
the time from date of incidence (defined as the date on
which the squamous cell carcinoma was histologically
confirmed) to death (any cause). PFS was defined as
the time period from date of incidence to death or the
first documented relapse, which was categorised as
local-regional recurrence or distant metastases. Patients
who developed a second primary tumour were censored
at the incidence date of that tumour. Survival rates wereestimated by means of the Kaplan-Meier method and
associations were analysed with the log-rank test. Multi-
variate analyses were performed using a forward selec-
tion procedure (p was set at <0.05 to enter the model)
in the Cox proportional hazards model to identify inde-
pendent prognostic factors. Intraclass correlation coeffi-
cients (with 95% confidence intervals [CI]) were
computed to determine interobserver variability of the
three investigators for percentages of CD44 and CD98
positive cells.3. Results
3.1. CD44/CD98 expression in the test cohort
CD44 and CD98-immunostaining were first per-
formed on a test cohort to detect a potential difference
between HPV-positive and HPV-negative cases and to
evaluate the chosen cut-off values. CD44 staining inten-
sity and percentage of CD44-positive cells were signifi-
cantly higher in HPV-negative tumours (n = 63)
compared to HPV-positive tumours (n = 25) (p = 0.03
and p = 0.002, respectively), as calculated by the
Mann-Whitney U test. CD98 staining intensity and per-
centage of CD98-positive cells were also significantly
higher (p < 0.001 for both) for HPV-negative tumours
compared to HPV-positive tumours. Distribution curves
for percentage of CD44/CD98-positive cells and CD44/
CD98 intensity for this test cohort are depicted in the
Supplementary data (S1).3.2. Patient and tumour characteristics
Next, we investigated the relation between CD44/
CD98 expression and survival in tumour biopsies
obtained from a large, consecutive cohort of 711 OPS-
CC patients. Patient and tumour characteristics are
depicted in Table 1. As published before, patients with
HPV-positive tumours had less advanced tumour
stages than patients with HPV-negative tumours, but
a more advanced nodal stage. A higher HPV-preva-
lence was found in squamous cell carcinomas in the
base of tongue and the tonsils compared to the other
oropharyngeal subsites (p < 0.001, with Bonferroni cor-
rection) [20].
With regard to differentiation, the majority of all
HPV-positive tumours (71.3%) were poorly differenti-
ated, while the majority of the HPV-negative tumours
(72.5%) were moderately differentiated. The intensity
and percentage of CD44 and CD98 positive cells were
not statistically different in poorly differentiated
tumours compared to well and moderately differentiated
tumours. This concerned HPV-positive as well as HPV-
negative tumours. Distribution curves for percentage of
CD44/CD98-positive cells and CD44/CD98 intensity
for the whole patient group are depicted in Fig. 1.
Table 1
Patient and tumour characteristics.
HPV-positive
OPSCC
HPV-negative
OPSCC
p-Value* HPV-positive OPSCC/CD98
high
p-Value** All cases
Number
(percentages)
Number
(percentages)
Number (percentages) Number
(percentages)
No. of cases 150 (21.1%) 561 (78.9%) 11 711
Age at diagnosis
Mean 61.0 60.6 p = 0.722 57.3 p = 0.31 60.7
Median 58.8 59.4 55.6 59.3
Gender p = 0.374 p = 0.93
Male 106 (70.7%) 375 (66.8%) 8 (72.7%) 481 (67.7%)
Female 44 (29.3%) 186 (33.2%) 3 (27.3%) 230 (32.3%)
Oropharyngeal Sub-site p < 0.001 p = 0.23
Tonsil 88 (58.7%) 226 (40.3%) 5 (45.5%) 314 (44.2%)
Base of tongue 48 (32.0%) 138 (24.6%) 4 (36.4%) 186 (26.2%)
Soft palate + uvula 9 (6.0%) 101 (18.0%) 2 (18.2%) 110 (15.5%)
Oropharynx nos 5 (3.3%) 96 (17.1%) 0 101 (14.2%)
Smoking p = 0.37
Never 44 (29.3%) 17 (3.0%) p < 0.001 1 (9.1%) 61 (8.6%)
Moderate (1–24 pack
years)
39 (26.0%) 70 (12.5%) 5 (45.5%) 109 (15.3%)
Heavy (>24 pack years) 66 (44.0%) 468 (83.4%) 5 (45.5%) 534 (75.1%)
Unknown 1 (0.7%) 6 (1.1%) 0 7 (1.0%)
T-stage p = 0.001 p = 0.93
T1 32 (21.3%) 68 (12.1%) 3 (27.3%) 100 (14.1%)
T2 45 (30.0%) 168 (29.9%) 3 (27.3%) 213 (30.0%)
T3 53 (35.3%) 184 (32.8%) 4 (36.4%) 237 (33.3%)
T4 20 (13.3%) 139 (24.8%) 1 (9.1%) 159 (22.4%)
Tx 0 2 (0.4%) 0 2 (0.3%)
N-stage p < 0.001 p = 0.08
N0 21 (14.0%) 233 (41.5%) 4 (36.4%) 254 (35.7%)
N1 21 (14.0%) 79 (14.1%) 1 (9.1%) 100 (14.1%)
N2 97 (64.7%) 218 (38.9%) 4 (36.4%) 315 (44.3%)
N3 11 (7.3%) 29 (5.2%) 2 (18.2%) 40 (5.6%)
Nx 0 2 (0.4%) 0 2 (0.3%)
Tumour differentiation p < 0.001 p = 0.26
Well 2 (1.3%) 30 (5.3%) 0 32 (4.5%)
Moderate 41 (27.3%) 407 (72.5%) 5 (45.5%) 448 (63.0%)
Poor 107 (71.3%) 124 (22.1%) 6 (54.5%) 231 (32.5%)
CD44 intensity p < 0.001 p = 0.07
Absent (0) 5 (3.3%) 1 (0.2%) 1 (9.1%) 6 (0.8%)
Weak (1) 12 (8.0%) 4 (0.7%) 0 16 (2.3%)
Moderate (2) 62 (41.3%) 111 (19.8%) 1 (9.1%) 173 (24.3%)
Strong (3) 71 (47.3%) 445 (79.3%) 9 (81.8%) 516 (72.6%)
CD44 expression p < 0.001 p = 0.66
610% 9 (6.0%) 4 (0.7%) 1 (9.1%) 13 (1.8%)
11–50% 37 (24.7%) 25 (4.5%) 1 (9.1%) 62 (8.7%)
51–75% 32 (21.3%) 29 (5.2%) 2 (18.2%) 61 (8.6%)
76–100% 72 (48.0%) 503 (89.7%) 7 (63.6%) 575 (80.9%)
CD98 intensity p < 0.001 p < 0.001
Absent (0) 76 (50.7%) 32 (5.7%) 0 108 (15.2%)
Weak (1) 41 (27.3%) 128 (22.8%) 0 169 (23.8%)
Moderate (2) 26 (17.3%) 255 (45.5%) 7 (63.6%) 281 (39.5%)
Strong (3) 7 (4.7%) 146 (26.0%) 4 (36.4%) 153 (21.5%)
CD98 expression p < 0.001 p < 0.001
610% 105 (70.0%) 70 (12.5%) 0 175 (24.6%)
11–25% 22 (14.7%) 151 (26.9%) 0 173 (24.3%)
26–50% 12 (8.0%) 146 (26.0%) 0 158 (22.2%)
51–100% 11 (7.3%) 194 (34.6%) 11 (100%) 205 (28.8%)
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Fig. 1. Results of the scoring percentages of (A) CD44- and (B) CD98-positive tumour cells and the intensities of the immunohistochemical
staining (C and D) in the whole patient group (n = 711). The data is represented as the mean observation of the three observers. Thick horizontal
lines represent the median value observed in the cohort.
Table 1 (continued)
HPV-positive
OPSCC
HPV-negative
OPSCC
p-Value* HPV-positive OPSCC/
CD98 high
p-
Value**
All cases
Number
(percentages)
Number
(percentages)
Number (percentages) Number
(percentages)
Treatment modalities p < 0.001 p = 0.44
SURG + RT 38 (25.3%) 167 (28.5%) 2 (18.2%) 198 (27.8%)
RT 28 (18.7%) 178 (31.7%) 3 (27.3%) 206 (29.0%)
CRT 45 (30.0%) 158 (28.2%) 4 (36.4%) 203 (28.6%)
RT + LND + RT
(brachytherapy)
35 (23.3%) 160 (8.6%) 1 (9.1%) 83 (11.7%)
Unknown 4 (2.7%) 17 (3.0%) 1 (9.1%) 21 (3.0%)
NOS means not otherwise specified, SURG means surgery, RT means radiotherapy, CRT means chemoradiation, and LND means lymph node
dissection.
 Independent t-test.
 Chi square.
* Human papillomavirus (HPV)-positive group compared to HPV-negative group.
** HPV-positive patients with CD98 expression >50% compared to HPV-positive patients with CD98 expression <50%.
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CD44 intensity as well as percentage of CD44-posi-
tive cells was compared between HPV-positive and
HPV-negative tumours. In Fig. 2, examples of strong
CD44-immunostaining (in an HPV-negative tumour)and weak CD44-immunostaining (in an HPV-positive
tumour) are shown. The CD44 intensity, dichotomised
as absent (0)/weak (1)/intermediate (2) (n = 192) versus
strong (3) (n = 519), was compared between HPV-posi-
tive and HPV-negative tumours. Strong CD44-staining
intensity (score = 3) was observed in 445 of 561
Fig. 2. (A) CD44-immunostaining of an human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC). (B) CD98-
immunostaining of an HPV-negative OPSCC. (C) Absence of p16INK4A-immunostaining of an HPV-negative OPSCC. (D) CD44-immunostaining
of an HPV-positive OPSCC. (E) Absence of CD98-immunostaining of an HPV-positive OPSCC. (F) p16 INK4A-immunostaining of an HPV-
negative OPSCC. (G) CD44-immunostaining of an HPV-positive OPSCC. (H) CD98-immunostaining of an HPV-positive OPSCC. (I) p16 INK4A-
immunostaining of an HPV-positive OPSCC. Pictures were taken through a 10 objective.
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(47.3%) HPV-positive tumours (p < 0.001, Pearson v2-
test). Furthermore, a high percentage of CD44-positive
cells (i.e. >75% of malignant cells stained) was found
in 72 of 150 HPV-positive tumours (48.0%) versus 503
of 561 HPV-negative tumours (89.7%). This was a sig-
nificant difference (p < 0.001) (Table 1). The interob-
server intraclass correlation coefficient (ICC) for
fraction of CD44-positive cells was 0.88 (95% CI:
0.87–0.90).
3.4. CD98 expression
CD98-immunostaining was less intense and a lower
percentage of tumour cells were stained compared to
CD44-immunostaining (Table 1). CD98-intensity was
dichotomised as absent (0)/weak (1) (n = 277) versus
intermediate (2)/strong (3) (n = 434). Percentage of
CD98-positive cells was classified as ‘high’ if >50% of
tumour cells were stained, in concordance with previ-
ously published reports [15,16]. In Fig. 2, examples of
weak and strong CD98-immunostaining are depicted.
CD98 expression differed significantly between HPV-
positive and HPV-negative tumours. An intermediate
or strong CD98-staining intensity (score 2 or 3) was
observed in 401 of 561 (71.5%) HPV-negative
tumours compared to 33 of 150 (22.0%) HPV-
positive tumours (p < 0.001). Furthermore, HPV-positive tumours showed a significantly smaller percent-
age of tumour cells with CD98 expression than HPV-
negative tumours; a high percentage of CD98-positive
cells (i.e. >50% of malignant cells stained) was found
in 11 of 150 HPV-positive tumours (7.3%) versus 194
of 561 HPV-negative tumours (34.6%) (p < 0.001)
(Table 1). The ICC for percentage of CD98-positive cells
was 0.83 (95% CI: 0.81–0.84).
3.5. Associations between CD44/CD98 expression and
survival
There was no significant difference in survival
between the different treatment groups neither for
patients with HPV-negative tumours (p = 0.204) nor
for patients with HPV-positive tumours (p = 0.277),
after correcting for age and stage of disease.
A univariate survival analysis was performed to eval-
uate factors potentially associated with OS and PFS.
The analyses were subdivided for patients with HPV-
positive and HPV-negative tumours. Prognostic factors
entered in the univariate analysis were: age, nodal stage,
tumour stage, gender, number of pack years, CD44
intensity, percentage of CD44-positive cells, CD98
intensity and percentage of CD98-positive cells. In
HPV-negative patients, age, tumour size and nodal stage
were all individually associated with OS and PFS out-
comes. However, neither CD44 expression nor CD98
Table 2
Univariate models for overall and progression-free survival.
HPV-positive OPSCC HPV-negative OPSCC
Hazard ratio (95% Confidence
Interval)
p Value Hazard ratio (95% Confidence
Interval)
p Value
Overall survival
Age (per increase of 1 year) 1.05 (1.02–1.08) p < 0.001 1.02 (1.01–1.04) p < 0.001
Gender (male versus female) 0.79 (0.41–1.52) p = 0.47 0.81 (0.65–1.02) p = 0.07
Tumour size (T3-4 versus T1-2) 1.85 (1.03–3.35) p = 0.04 1.78 (1.42–2.22) p < 0.001
Nodal stage (N2-3 versus N0-1) 0.80 (0.43–1.47) p = 0.47 2.28 (1.84–2.82) p < 0.001
Pack Years p = 0.33 p = 0.21
PY: 1–24 PY versus 0 PY 1.56 (0.67–3.61) 1.28 (0.60–2.76)
PY: >24 PY versus 0 PY 1.75 (0.83–3.68) 1.60 (0.80–3.22)
CD44 intensity (score 3 versus score 0/
1/2)
1.51 (0.79–2.87) p = 0.21 0.92 (0.73–1.15) p = 0.46
CD44 percentage (675% versus >75%) 0.78 (0.44–1.40) p = 0.42 0.87 (0.62–1.22) p = 0.42
CD98 intensity (score 2-3 versus score
0–1)
1.51 (0.79–2.87) p = 0.21 0.92 (0.73–1.15) p = 0.46
CD98 percentage (650% versus >50%) 2.92 (1.30–6.54) p = 0.009 0.86 (0.69–1.07) p = 0.18
Progression-free survival
Age (per increase of 1 year) 1.05 (1.02–1.08) p < 0.001 1.02 (1.01–1.03) p = 0.006
Tumour size (T3-4 versus T1-2) 1.84 (1.04–3.27) p = 0.04 1.52 (1.21–1.91) p < 0.001
Gender (male versus female) 1.00 (0.56–1.84) p = 1.00 0.81 (0.64–1.02) p = 0.08
Nodal stage (N2-3 versus N0-1) 0.82 (0.45–1.51) p = 0.53 2.16 (1.73–2.69) p < 0.001
Pack Years p = 0.38 p = 0.63
PY: 1–24 PY versus 0 PY 1.65 (0.75–3.61) 1.01 (0.49–2.10)
PY: >24 PY versus 0 PY 1.58 (0.77–3.24) 1.17 (0.60–2.28)
CD44 intensity (score 3 versus score 0/
1/2)
1.62 (0.87–3.02) p = 0.13 0.93 (0.73–1.18) p = 0.54
CD44 percentage (675% versus >75%) 0.86 (0.49–1.51) p = 0.60 0.97 (0.67–1.40) p = 0.87
CD98 intensity (score 2-3 versus score
0–1)
1.62 (0.87–3.02) p = 0.13 0.93 (0.73–1.18) p = 0.93
CD98 percentage (650% versus >50%) 3.57 (1.66–7.68) p = 0.001 0.90 (0.71–1.13) p = 0.36
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HPV-positive patients, age, tumour size and percentage
of CD98-positive cells were prognostic factors for OS
and PFS.
HPV-positive patients with a high percentage of
CD98-positive cells (i.e. >50% of malignant cells
stained) had significantly worse 5-year OS and PFS rates
(36.4% and 27.3%, respectively) compared to patients
with a low percentage of CD98-positive cells (71.8%
and 69.8%, respectively) (Fig. 3). The percentage of
CD44-positive cells did not correlate with OS and PFS
survival rates in HPV-positive patients.
Multivariate analysis was performed to estimate the
association of all the analysed factors with OS and
PFS. Age (655 years), tumour size (T1-2) and nodal
stage (N0-1) were independent prognostic factors for
OS and PFS in HPV-negative patients. In HPV-positive
patients, smoking (624 pack years), tumour size (T1-2)
and a low percentage of CD98-positive cells (i.e. <50%
of stained tumour cells) were independent prognostic
factors for OS and PFS (Table 3).
4. Discussion
Over the past decades, CSCs have been identified in
multiple solid tumours and were implicated to play arole in resistance to anticancer treatments [22,23]. As
CSCs generally divide slowly and are rich in DNA repair
enzymes and detoxification mechanisms, treatment fail-
ure likely occurs due to ineffective killing of these CSCs
[24]. As many studies have shown that patients with an
HPV-positive OPSCC respond better to (chemo) radia-
tion than patients with an HPV-negative OPSCC, we
hypothesised that a possible explanation for this could
be lower percentages of CSCs in HPV-positive OPSCCs.
In this study, we evaluated the immunostaining patterns
of two CSC markers, CD44 and CD98, in both HPV-
positive and HPV-negative OPSCCs. Expression of both
CD44 and CD98 was significantly lower in patients with
an HPV-positive OPSCC. This suggests that HPV-
positive tumours may have lower numbers of CSCs,
which may be reflected by a better therapy response.
Therefore, we evaluated whether CD44 and/or CD98
expression could be of potential relevance for predicting
treatment in HPV-positive patients. CD44 expression
was not associated with survival neither in HPV-positive
patients nor in HPV-negative patients. This is likely due
to the fact that CD44 was abundantly expressed in
almost all tumours.
Several studies have shown that CD44 expression
might be used as an outcome predictor in head and neck
cancer [7,10], but we cannot confirm this observation.
Fig. 3. (A) 5-year overall survival (OS) curves for patients with an
human papillomavirus (HPV)-positive oropharyngeal squamous cell
carcinoma (OPSCC) and high percentage of CD98-positive cells (i.e.
>50% of malignant cells stained; red line) versus patients with a low to
intermediate percentage of CD98-positive cells (i.e. 650% of malignant
cells stained; blue line) (p = 0.006). (B) 5-year progression-free survival
(PFS) curves for patients with an HPV-positive OPSCC and high
percentage of CD98-positive cells (i.e. >50% of malignant cells stained;
red line) versus patients with a low to intermediate percentage of
CD98-positive cells (i.e. 650% of malignant cells stained; blue line)
(p < 0.001). (C) 5-year OS curves for patients with an HPV-negative
OPSCC and high percentage of CD98-positive cells (i.e. >50% of
malignant cells stained; red line) versus patients with a low to
intermediate percentage of CD98-positive cells (i.e. 650% of malignant
cells stained; blue line) (p = 0.176). (D) 5-year PFS curves for patients
with an HPV-negative OPSCC and high percentage of CD98-positive
cells (i.e. >50% of malignant cells stained; red line) versus patients with
a low to intermediate percentage of CD98-positive cells (i.e. 650% of
malignant cells stained; blue line) (p = 0.693). (For interpretation of
the references to colour in this figure legend, the reader is referred to
the web version of this article.)
Table 3
Multivariate models for overall and progression-free survival.
HPV-positive OPSCC
Hazard ratio (95% Confidence
Interval)
Overall survival
Age (per increase of 1 year) 1.06 (1.03–1.09)
Tumour size (T3-4 versus T1-2) 2.22 (1.19–4.16)
Nodal stage (N2-3 versus N0-1)
CD98 percentage (<50% versus
P50%)
0.23 (0.10–0.53)
Progression-free survival
Age (per increase of 1 year) 1.05 (1.03–1.08)
Tumour size (T3-4 versus T1-2) 2.28 (1.26–4.15)
Nodal stage (N2-3 versus N0-1)
CD98 percentage (<50% versus
P50%)
0.20 (0.09–0.45)
772 M.M. Rietbergen et al. / European Journal of Cancer 50 (2014) 765–773Although CD44 seems an interesting marker for CSC
enrichment in HNSCC, it is not optimal. In several stud-
ies it was shown that CD44 protein expression is not
only present on the basal cells (the compartment where
the stem cells are assumed to reside) but also on the
suprabasal cells, both on normal and malignant squa-
mous tissue [21,25–28]. Subtle differences in CD44
expression might by detected by FACS-sorting, but
quantification of CD44-immunostained tissue sections
is difficult considering the profuse CD44 expression
throughout normal and malignant squamous tissues.
In contrast, CD98 expression was restricted to cells in
the basal layer and was expressed on a more restricted
cell population than CD44, making CD98 more distinc-
tive than CD44. In HPV-negative patients, no associa-
tion was seen between CD98 expression and survival.
However, in patients with HPV-positive OPSCC, OS
and PFS were significantly worse for patients with a
high percentage of CD98-positive tumour cells.
At this moment, de-escalation trials are being per-
formed for patients with an HPV-positive OPSCC. We
suggest it might be useful to evaluate the presence of
CSC markers, such as CD98, in addition to HPV-status,
as a stratification marker. Consequently, patients with
an HPV-positive OPSCC, but a high fraction of
CD98-positive tumour cells, might better not be selected
for de-escalating oncological treatment. Although a
challenging and attractive idea, the use of CD98 as a
prognostic marker should first be preceded by a thor-
ough validation phase in prospective clinical trials.
The observation that CD98 expression was not asso-
ciated with survival in HPV-negative patients, suggests
that the molecular characteristics of these cells might
be more relevant than the mere numbers. This requires
additional investigation and characterisation of these
cells in responding and non-responding tumours.
In conclusion, most HPV-positive OPSCCs show low
expression levels of the CSC markers CD44 and CD98HPV-negative OPSCC
p Value Hazard ratio (95% Confidence
Interval)
p Value
p < 0.001 1.03 (1.02–1.05) p < 0.001
p = 0.01 1.51 (1.21–1.90) p < 0.001
2.33 (1.86–2.91) p < 0.001
p = 0.001
p < 0.001 1.03 (1.01–1.04) p = 0.001
p = 0.007 1.32 (1.05–1.67) p = 0.02
2.18 (1.73–2.74) p < 0.001
p < 0.001
M.M. Rietbergen et al. / European Journal of Cancer 50 (2014) 765–773 773compared to HPV-negative OPSCCs. Furthermore, OS
as well as PFS was markedly better for HPV-positive
patients with a low fraction of CD98-positive tumour
cells compared to HPV-positive patients with high frac-
tion of CD98-positive tumour cells. In the future, we
might use CD98 expression as an additional prognostic
marker for selection of HPV-positive patients in clinical
trials.
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